FPR2 and Sepsis: The study assessed plasma LXA4 levels and ALX/FPR2 receptor expression throughout the infection and evaluated the effects of receptor agonists (LXA4 and BML-111) and antagonists (BOC-2 and WRW-4) administered at early (1 h) and late (24 h) stages of sepsis [42].